826 NORTH PLANKINTON AVE. MILWAUKEE, WI 53203 Get Directions
826 NORTH PLANKINTON AVE. MILWAUKEE, WI 53203 Get Directions
Promentis Pharmaceuticals, Inc. is a pharmaceutical company developing novel compounds for the treatment of schizophrenia and other central nervous system disorders. Promentis' drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other diseases.
Impaired cortical function, due at least in part to altered glutamate signaling and oxidative stress, is a key event that likely contributes to a number of central nervous system (CNS) disorders. As a result, molecular mechanisms capable of regulating levels of either glutamate or glutathione (or both) represent novel and potentially promising treatment targets. Promentis believes that its approach takes broader account of the components within the glutamatergic system and possesses the potential to restore imbalances thought to be responsible for many CNS disorders, including schizophrenia, autism, and Parkinson's disease. Thus, Promentis is aggressively embarking on an effort to develop molecules that will redefine what is possible in the treatment of these conditions.
© Dun & Bradstreet, Inc. 2024. All rights reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.